Although it is well-established that amyloid-β and tau play a central role in AD1, HDAC I reduction sheds light on the mechanism by which these pathologies interact in the brain tissue to determine disease progression, which is an important unanswered question in AD. This evidence concerns the gene APP and Alzheimer disease.